These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 8461649)
1. Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group. BMJ; 1993 Jan; 306(6873):306-7. PubMed ID: 8461649 [No Abstract] [Full Text] [Related]
2. [HIV infection among type A and B hemophiliacs]. Vicariot M; Fressinaud E; Fiks M; Fonlupt J; Berthier AM; Guerois C; Fimbel B Rev Fr Transfus Hemobiol; 1993 Oct; 36(5):417-26. PubMed ID: 8259952 [TBL] [Abstract][Full Text] [Related]
3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466 [TBL] [Abstract][Full Text] [Related]
4. Haemophilia treatment in the United Kingdom from 1969 to 1974. Biggs R Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406 [TBL] [Abstract][Full Text] [Related]
5. Antibody to hepatitis C (anti C 100-3) in French hemophiliacs. Maisonneuve P; Laurian Y; Guerois C; Verroust F; Ferrer Le Coeur F; Couroucé AM; Noel L Nouv Rev Fr Hematol (1978); 1991; 33(3):263-6. PubMed ID: 1956764 [TBL] [Abstract][Full Text] [Related]
6. Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Levine PH; Britten AF Ann Intern Med; 1973 Feb; 78(2):195-201. PubMed ID: 4630527 [No Abstract] [Full Text] [Related]
7. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients. Heimburger N; Karges HE; Weidmann E Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638 [TBL] [Abstract][Full Text] [Related]
8. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia]. Pollmann H Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hemophilia. Meili EO Schweiz Med Wochenschr Suppl; 1991; 43():82-9. PubMed ID: 1843043 [No Abstract] [Full Text] [Related]
10. Hemophilia in childhood. McNeill GF; Schwartz E Pa Med; 1975 Jan; 78(1):51-3. PubMed ID: 1128902 [No Abstract] [Full Text] [Related]
11. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B. Levine PH N Engl J Med; 1974 Dec; 291(26):1381-4. PubMed ID: 4427642 [No Abstract] [Full Text] [Related]
12. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Schimpf K; Schwarz P; Kunschak M Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845 [No Abstract] [Full Text] [Related]
14. Transmissibility of human immunodeficiency virus in haemophilic and non-haemophilic children living in a private school in France. Berthier A; Chamaret S; Fauchet R; Fonlupt J; Genetet N; Gueguen M; Pommereuil M; Ruffault A; Montagnier L Lancet; 1986 Sep; 2(8507):598-601. PubMed ID: 2875320 [TBL] [Abstract][Full Text] [Related]
15. Factor concentrate prophylaxis for neonates with hemophilia. Buchanan GR J Pediatr Hematol Oncol; 1999; 21(4):254-6. PubMed ID: 10445886 [No Abstract] [Full Text] [Related]
16. Advances in the care and treatment of children with hemophilia. Manco-Johnson MJ Adv Pediatr; 2010; 57(1):287-94. PubMed ID: 21056743 [No Abstract] [Full Text] [Related]